SAREPTA THERAPEUTICS INC financial statements, including revenue, expenses, profit, and loss

The total revenue of AB3A for the last quarter is 383.19 M EUR, and it's 6.59% higher compared to the previous quarter. The net income of Q1 24 is 33.47 M EUR.